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Abstract 
 
The Effect of RNA Nucleic Aptamers on the Aggregation of Green Fluorescent 
Protein 
 
by 
 
Thomas Nguyen 
 
Protein aggregation can impact the product quality of pharmaceutical drugs in terms of 
efficacy, safety, and immunogenicity leading to economic and technical problems for 
biotechnology and pharmaceutical companies. Furthermore, protein aggregation can lead to 
the onset of a variety of diseases including amyloidosis, prion diseases, and other protein 
deposition disorders. To combat these issues, we investigated the potential of aptamers to 
prevent protein aggregation within our model, modified fluorescent protein. We have 
identified and successfully demonstrated that the previous selected AP3 aptamer has a high 
affinity for not only green fluorescent protein (GFP), but also to emerald GFP with a KD of 
199 nM. Our work has successfully demonstrated that protein aggregation can be inhibited 
upon binding of RNA aptamer.  
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I. Introduction 
A. Protein aggregation 
Proteins are complex amino acid macromolecules that are present in nearly every process 
within cells. Proteins are responsible for the structure, function, and regulation of body 
tissues and organs, making them an interesting biomolecule for scientists to understand [1]. 
With 20 different amino acids, thousands of different amino acid sequences can be formed. 
The sequences of amino acids determine the protein’s structure and function. However, in 
order for proteins to function properly, it is crucial for proteins to fold into a defined three-
dimensional structure known as the native fold. Generally, protein folding starts during 
protein synthesis at the ribosome and goes through structural intermediates before the native 
state is reached (Fig 1) [2]. 
 
Figure 1. Overview of cellular protein aggregation. Image from [2] 
Proteins have the potential to misfold and become non-functional due to different stresses, 
mutations in the nascent polypeptide, or translational errors [2]. Once the protein is misfolded 
in the cell, these intermediates can be refolded back to the native state with the help of 
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molecular chaperones or can be degraded by intracellular proteases in order to prevent a 
buildup of misfolded proteins [3]. If these networks of chaperones and proteases are overcome 
through persisting stress conditions, increased amounts of proteins, or in aged cells, the 
production of misfolded proteins will exceed the refolding or degradative capability of a cell 
leading to an accumulation of protein aggregates (Fig 1) [2].   
B. Factors that influence protein aggregates  
Many proteins have a natural propensity to aggregate due to the dynamic nature of their 
structures. Van der Waals forces, hydrogen bonds, disulfide linkages, and hydrophobic 
interactions hold protein shapes together. Environmental stresses that alter these forces and 
interactions could expose internal hydrophobic regions of a polypeptide chain causing an 
interaction of hydrophobic regions with other parts of the protein; a process that could lead to 
protein aggregation by stabilizing partially folded intermediates [4]. The main environmental 
stresses that determine the extent and rate of aggregation are the following: protein 
concentration, temperature, pH, ionic strength, and cosolutes [4].  
1. Protein Concentration 
An increase in protein concentration could result in decreased aggregation due to 
crowding effects, increased aggregation due to increased chance of association, and/or 
precipitation due to solubility limit [4]. The concept of macromolecular crowding expects a 
reduction in protein aggregation because crowding will favor formation of compact 
conformations over extended conformations of macromolecules [5]. In contrast, large 
concentrations of proteins would increase the degree of intermolecular protein-protein 
interactions, which would have a significant effect on protein aggregation [5]. Lastly, proteins 
can readily aggregate, precipitate, or crystallize when the protein concentration exceeds the 
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solubility limit – a process that is strongly dependent on solution conditions [6]. Thus, protein 
concentration is an important parameter in protein aggregation. 
2. Temperature 
Temperature is arguably the most critical environmental factor when handling proteins [5]. 
Increasing temperatures can theoretically reduce the activation energy of protein aggregation 
relative to thermal fluctuations, increase hydrophobic interaction, enhance the diffusion of 
proteins, and increase the frequency of collisions [5]. At decreasing temperatures, protein 
destabilization and denaturation may occur. Altogether, these processes will destabilize the 
protein and cause proteins to aggregate. However, in comparison to higher temperatures, low 
temperature-induced protein aggregation is often reversible and is not always an issue for 
proteins [5].  
3. pH 
pH is another important environmental factor in protein aggregation. The pH determines 
the surface charge of proteins, a factor that affects the intramolecular folding interactions, as 
well as intermolecular interactions of the protein [5]. With pH at extreme conditions, a 
protein’s surface can become heavily charged leading to an increase solubility and a decline 
in the aggregation of proteins due to an increase in repulsive intramolecular and 
intermolecular interactions [5]. 
4. Ionic Strength 
In close relation to pH, ionic strength is a key condition that impacts protein aggregation. 
Positive and negative ions can electrostatically interact with proteins and lead to altered 
charge-charge interactions and different conformational states, which causes proteins to 
	 4 
aggregate [5]. However, the overall effect of ionic strength on protein aggregation is protein-
dependent and dependent on the pH of the solution.  If neutralization of the protein surface 
charges favor protein folding/stability, reduction of such interactions by increasing ionic 
strength would destabilize the protein, which would open up hydrophobic patches in the 
protein structure and eventually lead to protein aggregation [5]. 
5. Cosolutes 
Cosolutes are small organic molecules that affect the solubility of proteins. 
Kosomotropes causes water molecules to favorably interact, which stabilizes intramolecular 
proteins. In opposition, chaotrope agents can disrupt the hydrogen-bonding network between 
water molecules. These interactions could reduce the stability of the native state of proteins 
by weakening the hydrophobic effect and causing protein to aggregate [7].  
C. Structural differences and types of protein aggregates 
In general, protein aggregates takes many forms and can be classified in the following 
categories: in vivo and in vitro, and ordered and disordered. Amyloid fibrils (both in vivo and 
in vitro) are examples of highly ordered β-sheet-rich aggregates, whereas inclusion bodies 
are examples of in vivo disordered aggregates. These in vivo aggregates are generally formed 
through persisting harsh stress conditions [4]. In contrast, disordered in vitro aggregates are 
formed during the refolding of denaturant-unfolded proteins at high protein concentrations, 
or under weakly native conditions at high protein concentrations [4].  Intramolecular β-sheets 
have been recognized as a common structural component of aggregates shared by both 
amorphous aggregates and amyloid fibrils [2]. The degree of β-sheet-rich organization is 
variable between different aggregate forms, with the highest present in amyloid fibrils, in 
which the β-sheets run perpendicular to the fibril axis (Fig 1) [8][9]. The morphology of the 
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protein is influenced by different denaturing conditions, which can potentially lead to 
different unfolding and aggregation mechanisms and pathways [10].  
D. Problems in biopharmaceuticals, biotechnology, and health from protein aggregation 
1. Neurodegenerative Diseases 
Amyloid protein aggregation and inclusion body formations are known to lead to the 
onset of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease, amyotrophic lateral sclerosis, and prion diseases [11]. According to the 
Institute for Neurodegenerative Diseases at the University of California, San Francisco, the 
global cost of Alzheimer’s disease in 2010 alone was $604 billion, or 1% of the global gross 
domestic product. In the U.S., people suffering from both Alzheimer’s and Parkinson’s 
diseases cost the nation $200 billion annually in patient care and lost productivity. 
Furthermore, this amount is estimated to increase to $1.1 trillion by 2050. Due to these 
overwhelming costs, it is crucial to find ways to improve the treatment of these diseases.   
Reasons for the toxicity of these protein aggregates in neurodegenerative diseases are still 
unknown. The most proposed reasons is that inclusions and aggregates represent the end 
stage of a molecular cascade and that the earlier steps in the cascade are linked to the 
pathogenesis of these diseases [11]. Many scientists today are working on understanding the 
molecular mechanisms of protein aggregation in order to develop therapeutics to these 
diseases. 
2. Protein based pharmaceutics 
Protein-based pharmaceuticals are among the fastest growing therapeutic agents targeting 
many different diseases including cancer, infectious diseases, and autoimmune diseases, and 
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AIDS/HIV [12]. However, protein aggregation presents a key challenge in the development 
and manufacturing of biologic formulations as it can impact the product quality in terms of 
efficacy, safety, and immunogenicity. During protein drug processing, the protein is exposed 
to conditions that could affect and alter the chemical and physical stability of the structure, 
leading to aggregation and precipitation [13]. This occurs most commonly during storage or 
the delivery of protein drugs. Thus, understanding how to solubilize these protein aggregates 
is crucial to ensure patient safety [4]. 
E. Current work in finding therapeutics to inhibit protein aggregation 
Many approaches have been developed to target and prevent protein aggregation. One 
method is to reduce the protein concentration in the system. One approach is the use of 
chemotherapy agents and proteasome inhibitors to reduce and eliminate the cells that are 
being used to secrete aggregated proteins [15]. However, in these studies the patients 
undergoing these treatments are often too sick to tolerate chemotherapy. Another protein 
reduction strategy that is being pursued in Alzheimer’s disease research is to inhibit or 
modulate the activity of specific enzymes such as β-secretases and/or γ-secretase in an effort 
to reduce the amount of Aβ peptides in the system [16]. However, this process can inhibit the 
production of other important cellular signaling proteins such as Notch, leading to serious 
toxicity in the human body [17]. Further knowledge about the assembly, regulation, and 
specificity of β-secretases and/or γ-secretase could potentially lead to a good safety profile for 
clinical trials. Another approach is to silence the gene by RNA-mediated interference (RNAi) 
to reduce the mRNA gene of the protein that is aggregated in the cell [18]. These approaches 
are the least mature and are explored in tissue culture and animal models [19]. There have also 
been data showing that proteases such as the Aβ-degrading enzyme neprilysin can degrade 
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monomeric and oligomeric Aβ-peptides [20]. Even so, there is a concern that the late state 
oligomers and amyloid fibrils will not be able to be degraded by these enzymes. 
Other therapeutic techniques focus on protein quality-control strategies. This approach 
seeks to understand and adjust intracellular and/or extracellular proteostasis pathways 
involved in protein folding, trafficking, and/or degradation [14]. Studies have shown that 
overexpressing the molecular chaperone Hsp70 in the cell significantly reducing protein 
aggregation which lead to a reduction in proteotoxicity and neurodegeneration in models of 
Huntington’s disease and Parkinson’s disease [21][22] . However, there are other studies 
showing that overexpression of the Hsp70 chaperones failing to lower the toxic load of 
aggregates causing motor deficits in mouse models [23].  
Another therapeutic approach is to stabilize the monomeric protein structure to prevent 
protein aggregation. Clinical trials results provided convincing evidence that the process of 
transthyretin (TTR) amyloidogenesis causes neurodegeneration and the presence of these 
small-molecules stabilizers slows and prevents the progression of neurological impairment 
[14]. Previous work has shown small molecules, like anti-inflammatory drug, diflunisal 
(Merck), binding and stabilizing TTR tetramer protein to inhibit protein aggregation [24]. 
Another strategy involves removing targeting amyloid fibrils from tissue by passive or 
active immunization against the amyloidogenic protein. With the use of antibodies, these 
biomolecules can bind to the monomeric, oligomeric, and fibrillar proteins, which can direct 
the degradation of these structures by phagocytic cells. This is currently being studied in 
Alzheimer’s disease, where immunization against Aβ-peptides causes an anti-Aβ immune 
response and is effective in removing these aggregates [25]. However, clinical trials have 
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shown that immunization against Aβ-patients with late-stage Alzheimer’s disease leads to 
deleterious outcomes, specifically aseptic meningoencephalitis in 6% of patients [26].  
While these methods have been promising in inhibiting protein aggregation, there is 
always an interest for other effective techniques that generate results with high efficacy and 
low toxicity. 
II. Motivation 
A. Green fluorescent protein (GFP)  
The extracellular and/or intracellular cross-β-sheet amyloid fibrils in patients of amyloid 
diseases are known as the histopathological hallmarks and serves as a basis for diagnosis. 
Even though human amyloid diseases consist of aggregates of diverse structure, the focus has 
always been on cross-β-sheet amyloid fibrils due to their well-defined structure, a 
characteristic in protein aggregates that has provided scientists the opportunity to target these 
structures [14]. Different fluorescent dyes that are known to bind to cross-β-sheet including 
Thioflavin T, Congo red, and other aromatic chromophores. These dyes are used extensively 
to understand, target, and characterize protein aggregation in the human body. However, data 
has shown certain dyes like Thioflavin T interacting with specific Aβ(1-40) residues and 
promote a rigid partially-folded conformation in solution, resulting in a more aggregation-
prone ensemble of peptides [27]. 
To circumvent the use of dyes, we used green fluorescent protein (GFP), a well-
characterized soluble globular protein that as our model for protein aggregation.  
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Figure 2.  A. victoria GFP beta-barrel architecture and approximate dimension drawing from protein data 
bank ID:1s7s. Image from [29]. 
 
The crystal structure of this 238 amino acid residue protein was solved, revealing that the 
cyclic tri-peptide chromophore is buried in the center of a cylinder formed by a tightly 
interwoven 11-stranded β-barrel structure (Fig 2) [30]. The encapsulation of the centrally 
located chromophore is responsible for a high quantum yield of fluorescence, inability of O2 
to quench the excited state, and resistance of chromophore titration of external pH in solution 
[30]. If the protein is unfolded or aggregated, the β-barrel structure is altered causing the 
intrinsic fluorescence of the protein to diminish. Thus, the characteristics of GFP 
fluorescence serve as our marker for protein aggregation.  
Over the last decade, mutagenesis strategies have been applied to the sequence encoding 
wild type GFP (wtGFP) to determine if different amino acid substitutions could optimize its 
spectral characteristics [29]. This led to the first spectral variant of Aequorea wtGFP known as 
Enhanced GFP (EGFP). EGFP had a distinct improvement over wtGFP due to its five-fold 
increase in fluorescence. Furthermore, EGFP matures more rapidly allowing fluorescence to 
be detected at earlier time points. The only issues with using EGFP is that it is slightly 
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sensitive to pH and has a weak tendency to dimerize, which causes an increased chance for 
protein aggregation [29]. In our study, we used an engineered version of EGFP, Emerald GFP 
(emGFP). This variant does not only contain the mutations featured in EGFP, but also 
includes four additional point mutations to improve the efficiency of maturation and folding 
at 37°C.  These features would minimize the chances that would cause our GFP to aggregate 
on its own, an important characteristic that can help us avoid irreproducibility in aggregation 
studies [29]. 
B. Supercharging proteins and its potential to inhibit protein aggregation 
Proteins are least soluble and are prone to aggregation when they are around their 
isoelectric point, where they have a net charge of zero [31]. In studies done by the Liu group at 
the Howard Hughes Medical Institute, they have explored the aggregation resistance of GFP 
in comparison to their supercharged variants of GFP [32]. They have created supercharged 
variants of GFP by identifying 29 different positions in the crystal structure of GFP that were 
highly solvent-exposed and mutated these amino acid residues to negatively charged residues 
for the negative variant and positively charged residues for the positive variant. They 
validated that their supercharged variants exhibited circular dichroism spectras (not shown) 
similar to their initial GFP control, starting GFP (stGFP), proving that these structures share 
similar secondary structures. In order to examine the effect of supercharging on aggregation 
resistance, different variants of GFP were induced to aggregate by thermal or chemical 
unfolding.  
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Figure 3. Aggregation of electrostatic surface potentials of starting GFP (stGFP), GFP(+36), and GFP(-30) by 
thermal and chemical denaturation. Thermal denaturation was induced by heating these samples for 1 min at 
100°C, and subsequently cooled for 2 hours at 25°C. Chemical unfolding was induced with 40% 2,2,2-
Trifluoroethanol at 25°C and monitored by right angle light scattering. Image from [32]. 
 
These results have demonstrated that protein aggregation occurred only for stGFP and not for 
the supercharged variants of GFP, which is shown by a loss in fluorescence for the stGFP 
sample and an increase in light scattering data in comparison to the supercharged samples 
(Fig 3). This shows that supercharged proteins lead to a significant modification in their 
intermolecular properties resulting in aggregation resistance.  A caveat of this approach is 
that in order to find the amino acids that are highly solvent-exposed for supercharging, the 
protein’s crystal structure must be well characterized [32]. Thus, alternative ways to 
‘supercharge’ proteins is a therapeutic approach for protein aggregation that should be 
explored.  
C. Aptamers 
Nucleic acid aptamers are small single-stranded DNA or RNA oligonucleotide sequences 
that bind to their targets with high affinity and specificity [33]. They are synthesized using 
an in vitro selection process, also known as Systematic Evolution of Ligands by Exponential 
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Enrichment (SELEX) [33]. Aptamers are similar to antibodies in the fact that they can bind 
onto multiple and different targets including proteins, phospholipids, sugars, nucleic acids, 
and whole cells. Aptamers are ideal candidates for clinical applications and could be 
advantageous over antibodies because they are i) smaller in size and lower complexity; ii) 
ease of synthesis and modification in vitro iii) their high affinity and specificity for their 
targets; iv) their structural flexibility enables aptamers to bind onto hidden epitopes, which 
cannot be targeted by antibodies; and v) they exhibit higher stability, with the potential to be 
easily stored until use [34]. 
Recently, the Kotlikoff group at Cornell University developed a group of RNA aptamers 
that bind GFP and other related fluorescent proteins with low nanomolar affinity through 
SELEX [36]. After their first 15 rounds of SELEX, through nitrocellulose filter-binding 
assays, they found the G16 aptamer was >80% enriched.  
 
Figure 4. Structure of AP3 aptamer and binding of fluorescent binding protein aptamers to different 
variants of GFP. (A) Schematic diagram of the secondary structure of AP3. (B) Comparison of G16 and AP3 
binding to fluorescent proteins showing that AP3 binds GFP and EGFP with higher affinity than G16. (C) 
Filter-binding assays shows similar binding of AP3 to GFP-related proteins. (D) Hill plot fits of data shown in 
(A) and (B). Image from [36]. 
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Through further optimization and after 12 more rounds of SELEX, they found that the AP3 
aptamer had a 5-fold greater affinity for both GFP and EGFP relative to G16 aptamer and 
also bound to YFP, and CFP (Fig 4B,C,D). Moreover, they confirmed that the AP3 and G16 
aptamers only has a high affinity for fluorescent proteins by comparing the aptamer binding 
to the coral protein Azami-green (Fig 4B).  
 
Figure 5. Fluorescence protein binding aptamers modify protein fluorescence. (A) Emission scan (475 nm 
excitation) of 25 nM GFP in the presence of increasing concentration of AP3. (B) Inhibition of GFP 
fluorescence by G16 and AP3 aptamers (475/505) (C) Fluorescence emission scans of 10 nM enhanced 
fluorescent proteins in the presence and absence of 250 nM AP3 aptamer. Image from [36]. 
 
In addition, they showed that upon binding of AP3 aptamer, there was a decrease in the 
fluorescence of GFP in a dose-dependent manner of its original level (Fig 5A). Interestingly, 
the effect on fluorescence was not equivalent for all GFP derivatives; the AP3 aptamer 
increased ECFP and EYFP fluorescence (Fig 5C). 
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Nucleic acid aptamer sequences are covalently linked through phosphodiester bonds, 
resulting in a hydrophilic backbone that is highly negative charged. Upon binding to its 
selected protein, these highly negative aptamers can potentially induce a ‘supercharge’ effect 
towards the protein of interest, resulting in a resistance towards aggregation. In addition to 
supercharging the protein aggregation is prevented due to an increase in steric hindrance or 
steric repulsions upon glycosylation of the protein [35]. With aptamers, proteins can have this 
same increase in steric hindrance upon aptamer binding leading to an inhibition in protein 
aggregation. Furthermore, with an increase of aptamer binding complexes, there would be a 
decrease in free monomeric protein in the system, which could also inhibit aggregation of the 
protein. Due to the properties of nucleic acid aptamers, the goal of this thesis is to investigate 
if the AP3 RNA aptamer inhibits emGFP aggregation by using the fluorescence of GFP as a 
marker for protein aggregation.  
III. Experimental Setup 
A. EmGFP Expression and Purification 
Recombinant emGFP expression and purification was achieved through the 
transformation of the pRSET-EmGFP expression vector (Invitrogen) in chemically 
competent Escherichia coli (E. coli) BL21(DE3) (Novagen) by traditional heat shock 
transformation methods. High-level expression of the soluble mature form of emGFP was 
achieved by growing E. coli cultures in LB broth at 37 °C with the induction of 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG). In order to prepare soluble extracts, the cells 
were collected by centrifugation and lysed using a Branson Sonifier in a lysis buffer 
containing 50 mM NaH2PO4, 300 mM NaCl and 10 mM Imidazole at pH 8.0. Protein 
purification was carried out in an IMAC column loaded with HisPur Ni-NTA resin 
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(ThermoFisher) using 50 mM NaH2PO4, 300 mM NaCl, and 20-50 mM imidazole at pH 8 a 
sthe wash buffer and 50 mM NaH2PO4, 300 mM NaCl, and 175 mM imidazole at pH 8 as the 
elution buffer. Other batches of emGFP was purified through Fast Protein Liquid 
Chromatography (FPLC) with a 5 mL HisTrap HP column (GE Healthcare Life Sciences), 
using the same wash and elution buffer. All GFP containing fractions were pooled and 
dialyzed against 1X PBS. Aliquots were frozen in liquid nitrogen and then stored at -80 °C 
until use. The purity of GFP was confirmed using SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) and stained with Coomassie Brilliant Blue R-250 (Sigma Aldrich). The 
following gels were imaged using Foto/Analyst Express (Fotodyne) and the Amersham 
Typhoon 5 Biomolecular Imager (GE Healthcare Life Sciences).  
B. In Vitro Synthesis of RNA Aptamer 
In order to generate the template for in vitro transcription, a PCR product was amplified 
from the DNA template sequence with the corresponding primer pairs, which contained the 
T7 promoter. The AP3 was made by in vitro transcription with T7 RNA polymerase (Kapa 
Biosystems) using the PCR products as the template. The RNAs were extracted by phenol-
chloroform method. The quality of the RNAs was verified using 40:1 8% Native PAGE and 
stained with SYBR-Gold and imaged using a Foto/Analyst Express (Fotodyne). The purified 
RNA was stored in -80 °C. Prior to using these aptamer stocks, the RNA was heated at 80°C 
for 5 minutes and cooled at room temperature for 30 minutes in order to refold the aptamer 
into its correct structure.  
C. Aptamer-Binding Assays 
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For electrophoretic mobility shift assays (EMSA), all binding assays were prepared in 1X 
PBS 5 mM MgCl2 (pH 7.5). A typical binding reaction contained different amount of emGFP 
with a constant concentration of AP3 aptamer incubated at 37°C for 30-60 min before 
loading on a 79:1 12% Native polyacrylamide gels. Gels ran at 250 V for 3 hours at 4°C then 
stained using SYBR-Gold (Invitrogen). The exposed screens were scanned with the 
Amersham Typhoon 5 Biomolecular Imager (GE Healthcare Life Sciences) and analyzed 
with ImageQuant software. Other images were taken using the Foto/Analyst Express upon 
excitation using a Dark Reader transilluminator (Clare Chemical). 
For fluorescence anisotropy assays, binding assays were prepared in 1X PBS 5 mM 
MgCl2 (pH 7.5). Binding reactions consist of a serial dilution of aptamer with constant 
emGFP incubated at 37°C for 30-60 min. Anisotropy measurements were carried out on the 
FluoroMax-4 Spectrofluorometer (Horiba). 
D. Fluorescence measurements and melting curves 
Single fluorescence measurements and emission curves were carried out on the 
FluoroMax-4 (Horiba). For high throughput data sets, fluorescence measurements and 
emission curves were produced using the Infinite M200 PRO Multimode Microplate Reader 
(Tecan). Melting curves were also carried on using the FluoroMax-4 (Horiba) with a 
temperature heat controller.  
E. Methods of aggregation 
Before inducing the protein, stock emGFP aggregates were pelleted centrifugation at 
13,000 rpm by a Symphony 2417R centrifuge (VWR). The supernatant was collected and the 
concentration of protein was determined using the Nanophotometer P300 (Implen). 
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For thermal unfolding induced aggregation, highly concentrated emGFP samples 
denatured by heating the solution at 95°C for at different time points using a digital heat 
block. Samples were then cooled at room temperature for an hour before fluorescence 
measurements using Tecan Microplate Reader. 
For chemical unfolding induced aggregation, emGFP samples were denatured using 
different concentrations of 2,2,2-trifluoroethanol (TFE). Aggregated samples were analyzed 
using dynamic light scattering at 173º from Zetasizer Nano (Malvern) and fluorescence 
measurements using Tecan Microplate Reader. 
For lyophilization and shaking/shearing induced aggregation, 500 µL emGFP samples 
were first lyophilized using Freeze Zone 4.5 (Labconco) in 2 mL eppendorf tubes.   
 
Figure 6. Schematic of lyophilization and shaking/shearing induced aggregation method. 
 
After resuspension of the lyophilized powder using different volumes of 1X PBS, an egg-
shaped teflon spin bar 3/8”X3/16” (VWR) stirred the solution at 120 rpm using a stir plate in 
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a 37°C warm room for 48 hours. Eventually, aggregation through shearing/shaking was 
completed by adding 3mm polystyrene glass beads (Fisher Scientific) into 96-well plates and 
shaken in the Tecan Microplate Reader at 40°C orbitally for 90 hours at 432 rpm. 
Fluorescence measurements and optical density measurements were done using the Tecan 
Microplate Reader and Nanophotometer P300 (Implen). Fluorescence measurements were 
carried out on the supernatant of the samples after pelleting the aggregates through 
centrifugation.  
F. Statistical Analysis 
Results are expressed as mean ± SD. Student’s unpaired t-test was used to determine the 
statistical differences of aggregation results using GraphPad Software. (*P values <0.05, **P 
values <0.01, and ***P values <0.001. NS = not significant) 
IV. Results 
A. Expression and purification of emGFP 
Initial expression was done in small scales. Thus, purification was first performed using 
an IMAC column loaded with HisPur Ni-NTA resin. Following purification, SDS-PAGE was 
used to determine the purity of the protein.   
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Figure 7. SDS-PAGE of emGFP fractions after purification from IMAC column loaded with HisPur Ni-
NTA resin. The following concentrations of imazadole in mM concentrations are provided above in the gel 
image. The protein was washed with 11 column volumes of 20 mM imizadole and eluted through a gradient of 
different imizadole concentrations of up to 125 mM imizadole. 
 
Purification using the IMAC column was effective shown by the single band at the molecular 
weight of emGFP (~27 kDa) (Fig 7). Additionally, expression and purification produced a 
high yield of 450 µL of 10 mg/mL emGFP or 376 µM emGFP.  
 
Figure 8. SDS-PAGE of emGFP fractions after purification from FPLC using a gradient of different 
imizadole concentrations. The protein was washed with 11 column volumes of 20 mM imizadole and eluted 
through a gradient of different imizadole concentrations up to 175 mM imizadole. 
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When purifying emGFP at larger batches, purification was completed using the FPLC using a 
5 mL HisTrap HP column. Due to the impurities present from the SDS-PAGE image 
produced from FPLC purification (Fig 8), following batches of protein were washed longer at 
20 mM imizadole, and the protein was eluted at a lower concentration of imizadole to ensure 
purity of emGFP (not shown). Overall, these gel images have shown that emGFP was 
successfully expressed and purified.  
B. Purity of AP3 aptamer 
After synthesizing the AP3 aptamer through in vitro transcription, the purity of the RNA 
aptamer was tested by running the samples onto a 40:1 8% native polyacrylamide gel. 
 
Figure 9. 29:1 8% Native polyacrylamide gel of purified AP3 Aptamer after staining with SYBR-Gold. 
 
A single high intensity band at around 143 nt proved that the AP3 aptamer was synthesized 
and purified with a high yield of 450 µL of 2.190 mM of RNA (Figure 9). This same aptamer 
was used for future tests.  
C. EmGFP-AP3 binding affinity determination 
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The AP3 aptamer has only been tested to bind to wtGFP and EGFP [37]. However, there 
has not been any data showing whether the AP3 aptamer has an affinity towards emGFP. In 
order to confirm the binding of the aptamer, EMSA and fluorescence anisotropy assays were 
carried out. 
 
Figure 10. EMSA assay of AP3 aptamer with emGFP. EMSA images were taken using Foto/Analyst 
Express and excited using a Dark Reader Transilluminator. The first 9 lanes correspond to the free aptamer and 
emGFP controls. The following 11 lanes represent a constant concentration of 0.24 µM AP3 with a 2X serial 
dilution of emGFP starting from 1.7 µM emGFP. 
 
The dark reader excites both emGPP and SYBR-Gold at a broad range of wavelengths at 
pure visible blue light. Through this process of excitation, a third band at a higher molecular 
weight is produced (shown by blue arrow) and is expected to be the AP3-emGFP complex 
(Fig 10). 
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Figure 11. EMSA assay of AP3 aptamer with emGFP. The first 9 lanes correspond to the free aptamer and 
emGFP controls. The following 11 lanes represent a constant concentration of 0.24 µM AP3 with a 2X serial 
dilution of emGFP starting from 20 µM emGFP. (A) Image of SYBR-Gold stained EMSA assay using 
Foto/Analyst Express (Fotodyne), which was excited using the Dark Reader transilluminator. (B) Typhoon 
image of SYBR-Gold stained EMSA assay (C) Hill plot equation fit of data shown in (B) using OriginPro 2015. 
 
From the typhoon image (Fig 11B), it is difficult to detect the bound complex (gray arrow in 
Fig 11A) since the peak excitation wavelength from typhoon (488 nm) is close to that of 
emGFP (487 nm) causing overexposure of the emGFP band (Fig 11B). However, the 
typhoon image has shown that increasing concentrations of emGFP results in lower aptamer 
band intensities. By comparing the ratio of the band intensities of free aptamer (the lowest 
band produced on the gel in Fig 11B) in the aptamer bound complexes to the aptamer control 
band intensity (lane 1 in Fig 11B), the fraction of the free aptamer of the EMSA assay over a 
broad range of emGFP concentrations produced a KD of 9 µM for AP3 (Fig 11C). 
To further confirm the binding of the AP3 aptamer, the changes in fluorescence 
anisotropy were analyzed upon AP3 aptamer binding.  
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Figure 12. Fluorescence Anisotropy measurements of AP3 bound emGFP. These anisotropy readings were 
produced from a constant concentration of 25 nM emGFP with different concentrations of AP3 aptamer. 
Fluorescence anisotropy was fitted through the Hill equation using OriginPro 2015.  
 
Fluorescence anisotropy measurements of the aptamer-emGFP complex in solution 
increased with higher concentrations of AP3, producing a KD of 199 nM for AP3 (Fig 12). 
The results produced from the EMSA and fluorescence anisotropy assays have proven that 
the AP3 binds to emGFP. 
D. The effect of AP3 aptamer on emGFP fluorescence 
From previous studies, the AP3 aptamer is known to alter protein fluorescence and 
causing an increase in ECFP and EYFP fluorescence and a decrease in EGFP fluorescence 
[36]. Here, we test the effect of AP3 on the emGFP fluorescence. 
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Figure 13. Fluorescent protein binding aptamers effect on protein fluorescence. (A) Emission curves of 25 
nM emGFP with various concentrations of AP3 Aptamer was measured and excited at 475 nm using the Tecan 
Microplate Reader. (B) Peak fluorescence at different concentrations of AP3 aptamer shown in (A). 
 
In comparison to previous studies, it is unclear how the aptamer effects the fluorescence of 
emGFP. Shown from the peak values from the emission curve after baseline subtraction, 
there is no clear trend of a dose-dependent decrease or increase in the fluorescence of emGFP 
(Fig 13B). Due to this, fluorescence data should not be fully trusted unless there is a clear 
indication that the protein has aggregated or has lost most of its fluorescence.    
E. Finding a method to induce aggregation 
1. Thermal and Chemical induced aggregation 
Unfolded proteins can easily lead to the aggregated state during the refolding process 
since they can undergo different intermediate states [37]. Hence, thermal denaturation and 
chemical denaturation was utilized to aggregate emGFP.  
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Figure 14. Melting curve of 80 µM emGFP from peak fluorescence measurements using FluorMax-4 
(475/514 nm). 
 
Before testing the effects of thermal denaturation on the aggregation of emGFP, a melting 
curve of the protein shows full denaturation at ~95ºC shown by the steady baseline 
fluorescence after this temperature (Fig 14). This temperature was used for further thermal 
induced aggregation steps.  
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Figure 15. Thermal denaturation induced aggregation of 70uM emGFP. (A) Images of eppendorf tube 
samples of emGFP after excitation using UV-Lamp (254 nm) from thermally induced aggregation. (B) 29:1 8% 
Native Gel of tube samples in (A). (C) Fluorescence of different thermally induced aggregation conditions 
(475/514 nm) in comparison to the control using Tecan Microplate Reader. (D) Zoomed-in fluorescence curve 
from (C). 
 
Thermal treatment induced protein aggregation shown by the aggregates stuck in the 
wells of the gel in comparison to the control (Fig 15B). Also, the fluorescence of the protein 
dramatically decreased proving that the emGFP has misfolded, lost its function of 
fluorescence, and aggregated (Fig 15A,C,D).  
Protein unfolding induced aggregation was also carried out using a common protein 
chemical denaturant, 2,2,2-trifluoroethanol (TFE) [38].  
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Figure 16. Chemical denaturation induced aggregation. (A) Dynamic Light Scattering of 60 uM emGFP 
aggregated using 40% TFE (B) Fluorescence of different chemically induced aggregation conditions (475/514 
nm) in comparison to the control using Tecan Microplate Reader.  
 
When analyzing the dynamic light scattering results, it is known that a higher derived count 
rate originates from higher concentration of particles, larger particles, or a combination of 
both. Taking advantage of these properties, the effectiveness of this chemical denaturant was 
tested by analyzing the derived count rate and fluorescence of our fluorescent protein. After 
the addition of 40% TFE to highly concentrated emGFP, there was a significant increase in 
derived count rate over time (Fig 16A). Furthermore, the optical density (A600) of the solution 
before and after the addition of the TFE was recorded resulting in an increase of 0.001 to 
0.435 respectively. Both of these results show that emGFP successfully aggregated through 
chemical unfolding. Further, the aggregation of emGFP upon different concentrations of TFE 
was tested. The fluorescence of emGFP increased with the amount of TFE, showing that 
lower concentration of TFE led to less emGFP aggregates in solution (Fig 16B). Even though 
these methods of unfolding induced aggregation were successful, these denaturation 
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conditions could also affect the folding and structure of the AP3 aptamer. As a result, other 
methods were explored to aggregate emGFP.  
2. Agitation induced aggregation 
Shaking and shearing could potentially induce protein aggregation through enhanced 
air/water interfaces. During this process, the hydrophobic property of the air relative to water 
induces protein alignment at the interface, maximizing exposure of the hydrophobic patches 
in the protein to the air, leading to misfolding and aggregation of the protein [39]. However, 
the impact of agitation in protein aggregation only occurs upon high shear forces [40]. To 
confirm if this method would work for our protein, agitation induced aggregation was tested.  
 
Figure 17. Aggregation kinetics of 60 µM emGFP at different volumes. Fluorescence measurements 
(475/514 nm) were agitated on a Tecan Microplate Reader at 40°C with polystyrene beads.  
 
Different volumes of high protein concentrated solution were added to the tecan platereader 
to help us determine which volume was best for this method of aggregation. These results 
have shown a constant slope of fluorescence in both the control and shaking samples over a 
65 hour time frame (Fig 17). In addition, the fluorescence dramatically decreased for the 
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samples with polystyrene beads. A possible explanation would be that the polystyrene beads 
and potential aggregates in solution could scatter the fluorescence, leading to a decrease in 
fluorescence. However, the optical density was measured between each of the samples and 
there were no differences between the measurements of the samples (not shown) showing 
that protein aggregation did not occur. 
3. Lyophilization and agitation induced aggregation 
Lyophilization is a common technique for the preparation of protein products. They can 
promote protein aggregation, both non-convalently and covalently, due to both freezing and 
drying stresses [41]. We combined lyophilization with shaking/shearing stresses in order to 
aggregate emGFP.  
 
Figure 18. Aggregation of emGFP from the combination of lyophilization and shearing/shaking. 500 µL of 
6 µM of emGFP was first lyophilized then resuspended at the volumes used above. The samples were then 
aggregated at 37°C using a stir rod. The control samples was lyophilized emGFP samples without stir rods. 
Samples were agitated in 1X PBS, 5 mM MgCl2 before lyophilization. 
 
The combination of both lyophilization and shaking/shearing led to aggregation shown by the 
dramatic decrease in fluorescence in the samples in comparison to the controls (fig 18). In 
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addition, a lower amount of protein was needed for aggregation making this method of 
aggregation approachable since there is a limited amount of AP3 aptamer. As a result, this 
method of protein aggregation was used to understand protein aggregation for future tests. 
F. Effect of AP3 aptamer on the aggregation of emGFP 
The effect of AP3 aptamer on emGFP aggregation was evaluated by the combination of 
lyophilization and agitation as the method of aggregation with the use of polystyrene beads 
instead of stir rods to overcome irreproducibility issues. The process of lyophilization would 
further help RNA aptamers to retain its structure even in the aggregation condition of the 
protein, avoiding the problem of RNA aptamer misfolding. 
 
Figure 20. Effect of AP3 Aptamer on the aggregation of emGFP from samples. (A) Monitoring the amount of 
aggregates of emGFP with and without AP3 aptamer through optical density measurements of non-lyophilized 
(gray), lyophilized (blue), and a combination of lyophilized and shearing/shaking induced aggregation samples 
(red). (B) Observing the fluorescence of the aggregation of lyophilized emGFP with and without AP3 aptamer. 
The error bars represent the standard of the mean of three independent experiments with the sample size being 
N=3 (*P values <0.05, **P values <0.01, and ***P values <0.001. NS = not significant) 
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Our results showed that the process of lyophilization as a method of aggregation alone 
does not lead to a significant amount of emGFP aggregation (Fig 20A). Due to these issues, 
we’ve decided to measure only the emission of the lyophilized samples with and without 
aggregation (Fig 20B). Through lyophilization and agitation, emGFP aggregation occurred 
without the AP3 aptamer shown by a significant increase in OD600 as well as a significant 
decrease in fluorescence. Further, the samples of emGFP aggregation with AP3 aptamer did 
not aggregate shown had no significant changes in OD600 and fluorescence values. This data 
shows that the protein aggregation can be inhibited upon binding of the AP3 aptamer.  
2. Discussion 
We have demonstrated that the previously selected AP3 aptamer has high binding affinity 
not only for GFP, but also for emGFP, the modified version of this protein. This aptamer 
displays an affinity for emGFP with an apparent KD of 200 nM shown from anisotropy and 
EMSA assays. We further revealed that upon binding of the AP3 aptamer, the emitted 
fluorescence could either increase or decrease, which was different in comparison to GFP 
and EGFP. We successfully devised a reproducible technique to aggregate emGFP by 
combining lyophilization and shaking/shearing the protein with a polystyrene glass bead. 
Upon binding of the AP3 aptamer, our results showed an inhibition in aggregation analyzed 
from the optical density and emission of emGFP.  
Due to the discrepancy in KD from EMSA and anisotropy measurements, other tests to 
obtain a more accurate measurement of KD could be useful to fully confirm the binding of the 
aptamer. When using SYBR-Gold, uneven staining of the nucleic acid sequences could 
occur, leading to a large inaccurate calculation of KD. In order to clearly detect the aptamer 
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and protein complex in the native gel and to find a more precise measurement of KD, use of 
fluorophore-labeled RNA aptamer with an emission peak wavelength far from emGFP would 
be useful. Isothermal titration calorimetry (ITC) experiments would also be useful by 
providing a more accurate measurement of KD of the RNA aptamer towards emGFP.  
Multiple groups have shown that nucleic acid aptamers can be selected against different 
peptides that can inhibit the aggregation of proteins like Mutant Huntington in Huntington’s 
disease [42], Amyloid Beta and Tau in Alzheimer’s disease [43][44], and even infectious prion 
proteins [45]. Our work also confirms that nucleic acid aptamers can inhibit the aggregation of 
model fluorescent protein, emGFP. Currently, our lab focuses on elucidating the sequence-
structure-function relationship of nucleic acid aptamers in order to rationally design aptamers 
de novo. Future directions focuses on building a database for therapeutic aptamers that can 
inhibit protein aggregation in effort to combat neurodegenerative diseases, as well as finding 
solutions to overcome the difficulties arising from aggregated-protein drugs in 
pharmaceutical industries. 
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Timeline 
	
	
	
	
	
 
A table of the dates which various parts of this setup were complete is given in Table A.1.  
 
Step Date 
Expression and Purification of emGFP June 2017-Sep 2017 
Reproducible method of aggregation Sep 2017-March 2017 
Synthesis of AP3 Aptamer Sep 2017-Oct 2017 
Aptamer-Binding Assays Oct 2017-March 2017 
AP3 aptamer on the aggregation of 
emGFP 
March 2017-May 2017 
Table A.1. Timeline of this thesis 
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